Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule

被引：0
|
作者：
Agustin A. Garcia
Mahesh Pujari
Susan Jeffers
Syma Iqbal
Heinz-Josef Lenz
Paul Beringer
Stan Louie
机构：
[1] University of Southern California,Norris Comprehensive Cancer Center, Keck School of Medicine
[2] University of Southern California,School of Pharmacy
[3] Women’s Cancer Research Institute,Cedars Sinai Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2005年 / 56卷
关键词：
Phase I; Clinical trial; Pharmacokinetics; Docetaxel; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 82
页数：7
相关论文
共 50 条
  • [31] Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies
    Advani, R
    Fisher, GA
    Lum, BL
    Jambalos, C
    Cho, CD
    Cohen, M
    Gollerkeri, A
    Sikic, BI
    CLINICAL CANCER RESEARCH, 2003, 9 (14) : 5187 - 5194
  • [32] Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors
    Lokich, J
    CANCER, 2000, 89 (11) : 2309 - 2314
  • [33] A phase I trial of irinotecan and Tomudex on an every three week schedule
    Stevenson, JP
    DeMaria, D
    Redlinger, M
    Hiller, K
    Mitchell, E
    Rose, L
    Friedland, D
    O'Dwyer, PJ
    ANNALS OF ONCOLOGY, 1998, 9 : 71 - 71
  • [34] Clinical phase I and pharmacology study of gemcitabine (2′,2′-difluorodeoxycytidine) administered in a two-weekly schedule
    Peters, G. J.
    Clavel, M.
    Noordhuis, P.
    Geyssen, G. J.
    Laan, A. C.
    Guastalla, J.
    Edzes, H. T.
    Vermorken, J. B.
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (02) : 212 - 221
  • [35] PEDIATRIC PHASE-I TRIAL AND PHARMACOKINETIC STUDY OF PIRITREXIM ADMINISTERED ORALLY ON A 5-DAY SCHEDULE
    ADAMSON, PC
    BALIS, FM
    MISER, J
    WELLS, RJ
    BLEYER, WA
    WILLIAMS, TE
    GILLESPIE, A
    PENTA, JS
    CLENDENINN, NJ
    POPLACK, DG
    CANCER RESEARCH, 1990, 50 (15) : 4464 - 4467
  • [36] Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule
    Puzanov, I.
    Lee, W.
    Berlin, J. D.
    Calcutt, M. W.
    Hachey, D. L.
    Vermeulen, W. L.
    Spanswick, V. J.
    Hartley, J. A.
    Chen, A. P.
    Rothenberg, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
    Krishnamurthi, Smitha S.
    Brell, Joanna M.
    Hoppel, Charles L.
    Egorin, Merrill J.
    Weaver, Karen C.
    Li, Xiaolin
    Ingalls, Stephen T.
    Zuhowski, Eleanor G.
    Schluchter, Mark D.
    Dowlati, Afshin
    Cooney, Matthew M.
    Gibbons, Joseph
    Overmoyer, Beth A.
    Ivy, S. Percy
    Remick, Scot C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 441 - 450
  • [38] Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
    Smitha S. Krishnamurthi
    Joanna M. Brell
    Charles L. Hoppel
    Merrill J. Egorin
    Karen C. Weaver
    Xiaolin Li
    Stephen T. Ingalls
    Eleanor G. Zuhowski
    Mark D. Schluchter
    Afshin Dowlati
    Matthew M. Cooney
    Joseph Gibbons
    Beth A. Overmoyer
    S. Percy Ivy
    Scot C. Remick
    Cancer Chemotherapy and Pharmacology, 2009, 63
  • [39] Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
    Mekhail, T
    Hutson, TE
    Elson, P
    Budd, GT
    Srkalovic, G
    Olencki, T
    Peereboom, D
    Pelley, R
    Bukowski, RM
    CANCER, 2003, 97 (01) : 170 - 178
  • [40] Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
    Rothenberg, ML
    Kuhn, JG
    Schaaf, LJ
    Rodriguez, GI
    Eckhardt, SG
    Villalona-Calero, MA
    Rinaldi, DA
    Hammond, LA
    Hodges, S
    Sharma, A
    Elfring, GL
    Petit, RG
    Locker, PK
    Miller, LL
    von Hoff, DD
    ANNALS OF ONCOLOGY, 2001, 12 (11) : 1631 - 1641
12345